Robert C. Bast researcher
Bast, Robert C.
Bast, Robert C. Jr. 1943-
Bast, Robert C. (Robert Clinton), 1943-
Bast, Robert C., Jr. (Robert Clinton), 1943-
Bast, Robert C. (1943- ).
Bast, Robert Clinton, 1943-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Bast, Robert C., jr.
VIAF ID: 85820191 (Personal)
Permalink: http://viaf.org/viaf/85820191
Preferred Forms
-
100 1 _ ‡a Bast, Robert C.
-
100 1 _
‡a
Bast, Robert C.
-
100 1 _ ‡a Bast, Robert C.
-
100 1 _
‡a
Bast, Robert C.
‡c
Jr.
‡d
1943-
-
100 1 _ ‡a Bast, Robert C. ‡d (1943- ).
-
100 1 _ ‡a Bast, Robert C. ‡q (Robert Clinton), ‡d 1943-
-
100 1 _ ‡a Bast, Robert C. ‡q (Robert Clinton), ‡d 1943-
-
100 1 _
‡a
Bast, Robert C.,
‡c
Jr.
‡q
(Robert Clinton),
‡d
1943-
-
100 1 _ ‡a Bast, Robert C., ‡c jr.
-
100 1 _
‡a
Bast, Robert Clinton,
‡d
1943-....
-
100 0 _
‡a
Robert C. Bast
‡c
researcher
4xx's: Alternate Name Forms (10)
5xx's: Related Names (2)
Works
| Title | Sources |
|---|---|
| ABMS compendium of cert. med. spec., 3rd ed., 1991: |
|
| DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy |
|
| DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters |
|
| DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. |
|
| DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells |
|
| Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer |
|
| Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo |
|
| Early detection of ovarian cancer: promise and reality |
|
| Elevated serum concentrations of CA-125 in patients with advanced endometriosis |
|
| Elevation of multiple serum markers in patients with stage I ovarian cancer. |
|
| Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma |
|
| Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix |
|
| Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer |
|
| Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition |
|
| Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. |
|
| Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate |
|
| Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells |
|
| Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. |
|
| Expression and amplification of the HER-2/ neu |
|
| Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer |
|
| Expression of cell regulatory proteins in ovarian borderline tumors |
|
| Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina |
|
| Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms |
|
| Expression of p16 induces transcriptional downregulation of the RB gene |
|
| Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV) |
|
| Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma |
|
| Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer |
|
| Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents |
|
| FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization |
|
| FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. |
|
| Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer |
|
| Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics |
|
| Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway |
|
| Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy |
|
| General keynote: molecular therapeutics and pharmocogenomics |
|
| Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling |
|
| Genetic analysis of early- versus late-stage ovarian tumors. |
|
| Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. |
|
| Growth regulation and transformation of ovarian epithelium |
|
| Guía para el uso y la interpretación de ensayos para el seguimiento de la autofagia (4ª edición) |
|
| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) |
|
| Gynecologic tumor markers |
|
| HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. |
|
| HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways |
|
| Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis |
|
| Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity |
|
| Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells |
|
| Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity |
|
| High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer |
|
| High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer |
|
| High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support |
|
| High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity |
|
| High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer |
|
| Holland-Frei cancer medicine |
|
| Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages |
|
| How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. |
|
| How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? |
|
| Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer |
|
| Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer |
|
| Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop |
|
| Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels |
|
| A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β |
|
| A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. |
|
| Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. |
|
| en scientific article |
|
| Screening for epithelial ovarian cancer [VR] c1992: |
|
| A study of the NB/70K and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients |
|
